US20200085902A1 - Composition and method for treating itching, burning and discomfort of the skin - Google Patents
Composition and method for treating itching, burning and discomfort of the skin Download PDFInfo
- Publication number
- US20200085902A1 US20200085902A1 US16/664,477 US201916664477A US2020085902A1 US 20200085902 A1 US20200085902 A1 US 20200085902A1 US 201916664477 A US201916664477 A US 201916664477A US 2020085902 A1 US2020085902 A1 US 2020085902A1
- Authority
- US
- United States
- Prior art keywords
- weight
- percent
- present
- amount
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 31
- 238000000034 method Methods 0.000 title claims description 9
- 208000003251 Pruritus Diseases 0.000 title description 33
- 230000007803 itching Effects 0.000 title description 14
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims abstract description 40
- 239000000499 gel Substances 0.000 claims abstract description 25
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 23
- 229960000890 hydrocortisone Drugs 0.000 claims abstract description 20
- 230000000699 topical effect Effects 0.000 claims abstract description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 18
- 244000144927 Aloe barbadensis Species 0.000 claims abstract description 15
- 235000002961 Aloe barbadensis Nutrition 0.000 claims abstract description 15
- 244000269722 Thea sinensis Species 0.000 claims abstract description 15
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 14
- 241000208681 Hamamelis virginiana Species 0.000 claims abstract description 14
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 14
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 14
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 210000004400 mucous membrane Anatomy 0.000 claims abstract description 10
- 241000208680 Hamamelis mollis Species 0.000 claims abstract description 9
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940046009 vitamin E Drugs 0.000 claims abstract description 9
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 9
- 239000011709 vitamin E Substances 0.000 claims abstract description 9
- 229940118846 witch hazel Drugs 0.000 claims abstract description 9
- 239000002674 ointment Substances 0.000 claims abstract description 7
- 239000003974 emollient agent Substances 0.000 claims abstract description 6
- 239000006210 lotion Substances 0.000 claims abstract description 6
- 239000000443 aerosol Substances 0.000 claims abstract description 5
- 239000006071 cream Substances 0.000 claims abstract description 5
- 239000007921 spray Substances 0.000 claims abstract description 5
- 241001116389 Aloe Species 0.000 claims description 8
- 229940098324 green tea leaf extract Drugs 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229940100611 topical cream Drugs 0.000 claims description 4
- 235000009569 green tea Nutrition 0.000 abstract 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 21
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 14
- YPFDHNVEDLHUCE-NMFSSPJFSA-N 1,1,2,2,3,3-hexadeuteriopropane-1,3-diol Chemical compound [2H]C([2H])(O)C([2H])([2H])C([2H])([2H])O YPFDHNVEDLHUCE-NMFSSPJFSA-N 0.000 description 7
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 7
- 244000020551 Helianthus annuus Species 0.000 description 7
- 235000003222 Helianthus annuus Nutrition 0.000 description 7
- 239000004264 Petrolatum Substances 0.000 description 7
- 229940073669 ceteareth 20 Drugs 0.000 description 7
- 229940081733 cetearyl alcohol Drugs 0.000 description 7
- 229960000541 cetyl alcohol Drugs 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000008367 deionised water Substances 0.000 description 7
- 229910021641 deionized water Inorganic materials 0.000 description 7
- DLAHAXOYRFRPFQ-UHFFFAOYSA-N dodecyl benzoate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC=CC=C1 DLAHAXOYRFRPFQ-UHFFFAOYSA-N 0.000 description 7
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 7
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 7
- 229940066842 petrolatum Drugs 0.000 description 7
- 235000019271 petrolatum Nutrition 0.000 description 7
- 229960005323 phenoxyethanol Drugs 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 6
- 206010068172 Anal pruritus Diseases 0.000 description 6
- 229940100524 ethylhexylglycerin Drugs 0.000 description 6
- 229940100460 peg-100 stearate Drugs 0.000 description 6
- 229940012831 stearyl alcohol Drugs 0.000 description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 description 6
- 239000013543 active substance Substances 0.000 description 4
- -1 aluminum ion Chemical class 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003860 topical agent Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000020238 sunflower seed Nutrition 0.000 description 2
- 206010000591 Acrochordon Diseases 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 231100000742 Plant toxin Toxicity 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000009544 Pruritus Ani Diseases 0.000 description 1
- 208000036741 Pruritus generalised Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 201000010618 Tinea cruris Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000002561 chemical irritant Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000008199 coating composition Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014881 enterobiasis Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 239000003123 plant toxin Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Definitions
- the present invention generally relates to the treatment of pruritus, more specifically relates to topical composition and method for alleviating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions in humans.
- Pruritus refers to an unpleasant sensation on the skin that urges to scratch or rub the area in order to obtain relief. Pruritus is commonly characterized by generalized and localized itching. Itching may be caused as a clinical manifestation of localized skin disorder, systemic disease, scratch reaction, insect bite, sunburn, wound healing and exposure to irritants such as plant toxins, chemicals, microbial proteins, and/or additional external mechanical, thermal and electrical stimuli. Common types of itching include anal itch, chemical itch, eczema, (including seborrheic dermatitis) pruritus dermatitis, diabetic skin itch, aging skin itch, foot-itch, jock itch, hives, dry winter skin itch and stress related scalp itch.
- pruritus can also occur in non-cutaneous sites such as mucous membranes.
- Perianal itching or “Pruritus ani” refers to the persistent itching and irritation of skin around the anus region. Perianal itching and burning not only causes physical discomfort but also results in distraction and socially awkward or embarrassing situations. Anal itching may be caused by chemical irritants in food, diarrhea, psoriasis, anal fissure, hemorrhoids, skin tags, diabetes, yeast infection and pinworm infection.
- topical agents such as emollients, ointments and oral drugs such as steroids, anti-inflammatory agents, local anesthetics, antihistamines, thermal stimulation and Ultraviolet phototherapy.
- topical agents such as emollients, ointments and oral drugs such as steroids, anti-inflammatory agents, local anesthetics, antihistamines, thermal stimulation and Ultraviolet phototherapy.
- Treatment with existing topical agents shows general but nonspecific benefit.
- Non-specific topical preparations including lotions, creams and oil-based ointments may provide softness and moisturizing effect on the dry skin, but causes an uncomfortable feeling and discomfort due to greasy nature of the preparation and soiling of garments.
- existing topical agents used for relieving perianal pruritus act slow and fail to provide complete cure from itching and burning.
- the present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions.
- the composition consisting essentially of Aloe barbadensis leaf gel, deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Hamamelis virginiana extract, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, Zemea propanediol and hydrocortisone.
- the present invention relates to a composition for treating localized pruritus.
- the composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel (0-50%), Hamamelis virginiana extract (0-50%), deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol in amounts up to 3 percent by weight.
- the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions.
- the method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract, 0 to 3% deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
- the present invention relates to a topical composition for treating discomfort of the skin and/or mucous membranes comprising therapeutically effective amounts of Aloe barbadensis leaf gel, Camellia sinensis leaf extract, Hamamelis virginiana extract, tocopheryl acetate, and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel.
- the hydrocortisone is present in an amount up to 1 percent by weight.
- the Aloe barbadensis leaf gel and Hamamelis virginiana extract are both present in an amount up to 50 percent by weight.
- the Camellia sinensis leaf extract and tocopheryl acetate are both present in an amount up to 3 percent by weight.
- the present invention relates to a pharmaceutical composition for treating discomfort of the skin comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream.
- the aloe leaf gel and witch hazel extract are both present in an amount up to 50 percent by weight.
- the green tea leaf extract and vitamin E are both present in an amount up to 3 percent by weight.
- the hydrocortisone is present in an amount up to 1 percent by weight.
- active agent drug
- active compound active compound
- pharmacologically active agent refers to a chemical material or compound which, when administered to humans, induces a desired pharmacologic effect. Included are derivatives and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired pharmacologic effect.
- “Pharmaceutically acceptable salt” refers to a salt of a compound, which possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts, formed with inorganic acids; acid addition salts formed with organic acids; or salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, aluminum ion; or coordinates with an organic base such as ethanolamine, and the like.
- a metal ion e.g., an alkali metal ion, aluminum ion
- coordinates with an organic base such as ethanolamine, and the like.
- carrier or “carrier” is composed of materials that are present in pharmaceutical formulation other than the active ingredient. Carriers are considered safe and effective and may be administered to an individual without causing undesirable biological side effects.
- carrier includes, but is not limited to, excipients, diluents, binders, lubricants, disintegrators, fillers, gliding agent and coating compositions.
- the present invention relates to a pharmaceutical composition for treating anal pruritus.
- the pharmaceutical composition comprises at least one active agent or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier.
- the composition is used for rapidly alleviating external anal itching and burning in humans.
- the present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions.
- the composition consisting essentially of Aloe leaf gel, deionized water, C12-15 alkyl benzoate, Green tea leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Witch Hazel extract, Sunflower seed oil, polyethylene glycol(PEG)-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate (Vitamin E), Zemea propanediol and hydrocortisone.
- the Aloe leaf gel of the composition is obtained from Aloe barbadensis leaves.
- Green tea leaf extract is obtained from Camellia sinensis leaves.
- Witch Hazel extract comprises an extract of Hamamelis virginiana and Sunflower seed oil is obtained from Helianthus annus seeds.
- the present invention relates to a composition for treating localized anal pruritus.
- the composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel, and Hamamelis virginiana extract are in amounts up to 50 percent by weight.
- Other components such as deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol are in amounts up to 3 percent by weight.
- the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions.
- the method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract and 0 to 3% by weight deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
- the composition is prepared in a form suitable for topical application on the skin surface of perianal region.
- the composition can be prepared in the form of cream, spray, lotion, solution, gel, emollient, ointment and aerosol form for application on the external perianal area of human body in order to alleviate itching.
- composition of the present invention is formulated in the form of a topical cream, which comprises the active agent and pharmaceutically acceptable carriers in a specific percent by weight ratio as mentioned in Table 1.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A topical composition for treating discomfort of the skin and mucous membranes comprising therapeutically effective amounts of Aloe barbadensis (aloe vera) leaf gel, Camellia sinensis leaf (green tea) extract, Hamamelis virginiana (witch hazel) extract, tocopheryl acetate (vitamin E), and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel. The Aloe barbadensis leaf gel and Hamamelis virginiana extract are both present in an amount up to 50 percent by weight. The Camellia sinensis leaf extract and tocopheryl acetate are both present in an amount up to 3 percent by weight. The hydrocortisone is present in an amount up to 1 percent by weight.
Description
- This application is a continuation of co-pending U.S. application Ser. No. 15/217,721, filed Jul. 22, 2016, expected to issue as U.S. Pat. No. 10,456,438 on Oct. 29, 2019.
- The present invention generally relates to the treatment of pruritus, more specifically relates to topical composition and method for alleviating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions in humans.
- “Pruritus” refers to an unpleasant sensation on the skin that urges to scratch or rub the area in order to obtain relief. Pruritus is commonly characterized by generalized and localized itching. Itching may be caused as a clinical manifestation of localized skin disorder, systemic disease, scratch reaction, insect bite, sunburn, wound healing and exposure to irritants such as plant toxins, chemicals, microbial proteins, and/or additional external mechanical, thermal and electrical stimuli. Common types of itching include anal itch, chemical itch, eczema, (including seborrheic dermatitis) pruritus dermatitis, diabetic skin itch, aging skin itch, foot-itch, jock itch, hives, dry winter skin itch and stress related scalp itch. Those who suffer from itch often note, persistent or recurrent attacks. Although usually occurring in the skin, pruritus can also occur in non-cutaneous sites such as mucous membranes. “Perianal itching” or “Pruritus ani” refers to the persistent itching and irritation of skin around the anus region. Perianal itching and burning not only causes physical discomfort but also results in distraction and socially awkward or embarrassing situations. Anal itching may be caused by chemical irritants in food, diarrhea, psoriasis, anal fissure, hemorrhoids, skin tags, diabetes, yeast infection and pinworm infection.
- Current treatment options for localized pruritus including perianal itching involves the use of topical agents such as emollients, ointments and oral drugs such as steroids, anti-inflammatory agents, local anesthetics, antihistamines, thermal stimulation and Ultraviolet phototherapy. However, treatment with existing topical agents shows general but nonspecific benefit. Non-specific topical preparations including lotions, creams and oil-based ointments may provide softness and moisturizing effect on the dry skin, but causes an uncomfortable feeling and discomfort due to greasy nature of the preparation and soiling of garments. In addition, existing topical agents used for relieving perianal pruritus act slow and fail to provide complete cure from itching and burning.
- Therefore, there is a need for an improved topical pharmaceutical preparation for providing rapid relief from pruritus by alleviating itching and burning in the perianal region of humans. There is also a need for improved composition and method for treating pruritus of the skin and/or mucous membranes including the perianal and vaginal regions in humans.
- The present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The composition consisting essentially of Aloe barbadensis leaf gel, deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Hamamelis virginiana extract, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, Zemea propanediol and hydrocortisone.
- In an embodiment, the present invention relates to a composition for treating localized pruritus. The composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel (0-50%), Hamamelis virginiana extract (0-50%), deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol in amounts up to 3 percent by weight.
- In an embodiment, the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract, 0 to 3% deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
- In an embodiment, the present invention relates to a topical composition for treating discomfort of the skin and/or mucous membranes comprising therapeutically effective amounts of Aloe barbadensis leaf gel, Camellia sinensis leaf extract, Hamamelis virginiana extract, tocopheryl acetate, and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel. The hydrocortisone is present in an amount up to 1 percent by weight. The Aloe barbadensis leaf gel and Hamamelis virginiana extract are both present in an amount up to 50 percent by weight. The Camellia sinensis leaf extract and tocopheryl acetate are both present in an amount up to 3 percent by weight.
- In an embodiment, the present invention relates to a pharmaceutical composition for treating discomfort of the skin comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream. The aloe leaf gel and witch hazel extract are both present in an amount up to 50 percent by weight. The green tea leaf extract and vitamin E are both present in an amount up to 3 percent by weight. The hydrocortisone is present in an amount up to 1 percent by weight.
- The terms “active agent,” “drug”, “active compound” and “pharmacologically active agent” are used interchangeably herein to refer to a chemical material or compound which, when administered to humans, induces a desired pharmacologic effect. Included are derivatives and analogs of those compounds or classes of compounds specifically mentioned which also induce the desired pharmacologic effect.
- “Pharmaceutically acceptable salt” refers to a salt of a compound, which possesses the desired pharmacological activity of the parent compound. Such salts include: acid addition salts, formed with inorganic acids; acid addition salts formed with organic acids; or salts formed when an acidic proton present in the parent compound is replaced by a metal ion, e.g., an alkali metal ion, aluminum ion; or coordinates with an organic base such as ethanolamine, and the like.
- Pharmaceutically acceptable “carrier” or “carrier” is composed of materials that are present in pharmaceutical formulation other than the active ingredient. Carriers are considered safe and effective and may be administered to an individual without causing undesirable biological side effects. The term “carrier” includes, but is not limited to, excipients, diluents, binders, lubricants, disintegrators, fillers, gliding agent and coating compositions.
- The present invention relates to a pharmaceutical composition for treating anal pruritus. The pharmaceutical composition comprises at least one active agent or its pharmaceutically acceptable salts thereof and at least one pharmaceutically acceptable carrier. The composition is used for rapidly alleviating external anal itching and burning in humans.
- In an embodiment, the present invention relates to a composition for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The composition consisting essentially of Aloe leaf gel, deionized water, C12-15 alkyl benzoate, Green tea leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Witch Hazel extract, Sunflower seed oil, polyethylene glycol(PEG)-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate (Vitamin E), Zemea propanediol and hydrocortisone.
- In an embodiment, the Aloe leaf gel of the composition is obtained from Aloe barbadensis leaves. Green tea leaf extract is obtained from Camellia sinensis leaves. Witch Hazel extract comprises an extract of Hamamelis virginiana and Sunflower seed oil is obtained from Helianthus annus seeds.
- The present invention relates to a composition for treating localized anal pruritus. The composition comprises hydrocortisone in an amount up to about 1 percent by weight and Aloe barbadensis leaf gel, and Hamamelis virginiana extract are in amounts up to 50 percent by weight. Other components such as deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate and Zemea propanediol are in amounts up to 3 percent by weight.
- In another embodiment, the present invention relates to a method for treating itching, burning and discomfort of the skin and/or mucous membranes including the perianal and vaginal regions. The method comprises administering topically a pharmaceutical composition consisting 0 to 50% by weight Aloe barbadensis leaf gel, 0 to 50% by weight Hamamelis virginiana extract and 0 to 3% by weight deionized water, C12-15 alkyl benzoate, Camellia sinensis leaf extract, ceteareth-20, cetearyl alcohol, cetyl alcohol, ethylhexylglycerin, glycerin stearate, Helianthus annus seed oil, PEG-100 stearate, petrolatum, phenoxyethanol, stearyl alcohol, tocopheryl acetate, and Zemea propanediol; and 0 to 1% by weight hydrocortisone.
- The composition is prepared in a form suitable for topical application on the skin surface of perianal region. The composition can be prepared in the form of cream, spray, lotion, solution, gel, emollient, ointment and aerosol form for application on the external perianal area of human body in order to alleviate itching.
- In this exemplary embodiment, the composition of the present invention is formulated in the form of a topical cream, which comprises the active agent and pharmaceutically acceptable carriers in a specific percent by weight ratio as mentioned in Table 1.
-
TABLE 1 Ingredient Ratio (Percent by Ingredient Weight) Hydrocortisone 0 to 1 Hamamelis virginiana extract 0 to 50 Camellia sinensis leaf extract 0 to 3 Tocopheryl acetate (Vitamin E) 0 to 3 Aloe barbadensis juice 0 to 50 Helianthus annuus seed oil 0 to 3 Cetyl alcohol 0 to 3 Glycerin stearate 0 to 3 Ceteareth-20 0 to 3 Stearyl alcohol 0 to 3 C12-15 alkyl benzoate 0 to 3 Cetearyl alcohol 0 to 3 Zemea propanediol 0 to 3 Phenoxyethanol 0 to 3 PEG-100 stearate 0 to 3 Ethylexylglycerin 0 to 3 Petrolatum 0 to 3 Aqua (deionized water) 0 to 3 - Although the invention has been described with reference to the disclosed embodiments, those skilled in the art will readily appreciate that the specific examples and studies detailed above are only illustrative of the invention. It should be understood that various modifications can be made without departing from the spirit of the invention. Accordingly, the invention is limited only by the following claims.
Claims (15)
1. A topical composition for treating discomfort of the skin and mucous membranes comprising therapeutically effective amounts of Aloe barbadensis leaf gel, Camellia sinensis leaf extract, Hamamelis virginiana extract, tocopheryl acetate, and hydrocortisone, formulated into a physical form selected from the group consisting of lotion, cream, emollient, ointment, spray, aerosol and gel.
2. The topical composition of claim 1 wherein the Aloe barbadensis leaf gel is present in an amount up to 50 percent by weight.
3. The topical composition of claim 1 wherein the Hamamelis virginiana extract is present in an amount up to 50 percent by weight.
4. The topical composition of claim 1 wherein the Camellia sinensis leaf extract is present in an amount up to 3 percent by weight.
5. The topical composition of claim 1 wherein the tocopheryl acetate is present in an amount up to 3 percent by weight.
6. The topical composition of claim 1 wherein hydrocortisone is present in an amount up to 1 percent by weight.
7. The topical composition of claim 1 wherein the Aloe barbadensis leaf gel is present in an amount up to 50 percent by weight, the Hamamelis virginiana extract is present in an amount up to 50 percent by weight, the Camellia sinensis leaf extract is present in an amount up to 3 percent by weight, the tocopheryl acetate is present in an amount up to 3 percent by weight, and hydrocortisone is present in an amount up to 1 percent by weight.
8. A pharmaceutical composition for treating discomfort of the skin comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream, lotion, emollient, ointment, spray, aerosol or gel.
9. The topical composition of claim 8 wherein the aloe leaf gel is present in an amount up to 50 percent by weight.
10. The topical composition of claim 8 wherein the witch hazel extract is present in an amount up to 50 percent by weight.
11. The topical composition of claim 8 wherein the green tea leaf extract is present in an amount up to 3 percent by weight.
12. The topical composition of claim 8 wherein the vitamin E is present in an amount up to 3 percent by weight.
13. The topical composition of claim 8 wherein hydrocortisone is present in an amount up to 1 percent by weight.
14. The topical composition of claim 8 wherein the aloe leaf gel is present in an amount up to 50 percent by weight, the witch hazel extract is present in an amount up to 50 percent by weight, the green tea leaf extract leaf extract is present in an amount up to 3 percent by weight, the vitamin E is present in an amount up to 3 percent by weight, and hydrocortisone is present in an amount up to 1 percent by weight.
15. A method for treating discomfort of the skin including the perianal and vaginal regions, the method comprising administering topically a pharmaceutical composition comprising aloe leaf gel, green tea leaf extract, witch hazel extract, vitamin E, and hydrocortisone, formulated in the form of a topical cream.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/664,477 US20200085902A1 (en) | 2016-07-22 | 2019-10-25 | Composition and method for treating itching, burning and discomfort of the skin |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/217,721 US10456438B2 (en) | 2016-07-22 | 2016-07-22 | Composition for treating pruritus |
US16/664,477 US20200085902A1 (en) | 2016-07-22 | 2019-10-25 | Composition and method for treating itching, burning and discomfort of the skin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/217,721 Continuation US10456438B2 (en) | 2016-07-22 | 2016-07-22 | Composition for treating pruritus |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200085902A1 true US20200085902A1 (en) | 2020-03-19 |
Family
ID=60990340
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/217,721 Active 2037-04-23 US10456438B2 (en) | 2016-07-22 | 2016-07-22 | Composition for treating pruritus |
US16/664,477 Abandoned US20200085902A1 (en) | 2016-07-22 | 2019-10-25 | Composition and method for treating itching, burning and discomfort of the skin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/217,721 Active 2037-04-23 US10456438B2 (en) | 2016-07-22 | 2016-07-22 | Composition for treating pruritus |
Country Status (1)
Country | Link |
---|---|
US (2) | US10456438B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115916183A (en) | 2020-01-10 | 2023-04-04 | 布里奥里生物技术公司 | Topical compositions containing rofecoxib and methods for their preparation and use |
CN111743984A (en) * | 2020-07-30 | 2020-10-09 | 张尚华 | Ginseng and cattail-flavor ointment for treating perianal eczema and pruritus and preparation method thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020127256A1 (en) * | 2001-03-01 | 2002-09-12 | Howard Murad | Compositions and methods for treating dermatological disorders |
US20100215726A1 (en) * | 2009-02-25 | 2010-08-26 | Peter Thomas Roth | Compositions for Diminishing the Appearance of Wrinkles |
BR112015025726A2 (en) * | 2013-04-09 | 2017-07-18 | Arch Chem Inc | multi-functional makeup for cosmetic formulations |
-
2016
- 2016-07-22 US US15/217,721 patent/US10456438B2/en active Active
-
2019
- 2019-10-25 US US16/664,477 patent/US20200085902A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180021396A1 (en) | 2018-01-25 |
US10456438B2 (en) | 2019-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6473134B2 (en) | Flunisolide topical composition and method of treatment | |
US11331326B2 (en) | Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid | |
KR100619228B1 (en) | Topical skin delivery anhydrous composition and a composition for topical skin treatment comprising the composition as a medicament | |
US20220287964A1 (en) | Topical formulations comprising cannabidiol, method of prep aring the composition and use thereof | |
US20130267490A1 (en) | Topical pharmaceutical composition comprising nanonized silver sulfadiazine and chlorhexidine gluconate | |
US7179475B1 (en) | Anhydrous topical skin preparations | |
EP3677265A1 (en) | Composition for preventing or treating sleep disorders | |
US20220273559A1 (en) | Cbd formulations and uses thereof | |
FI56931B (en) | FOERFARANDE FOER FRAMSTAELLNING AV ETT THERAPEUTIC ACTIVE STABILT TRETINOINGELPREPARAT UR VILKET TRETINOINET LAETT FRIGOERES OCH ABSORBERAS I HUDEN | |
US9572777B2 (en) | Topical pharmaceutical composition comprising nanonized silver sulfadiazine | |
US20030026819A1 (en) | Cream-to-powder dermatological composition | |
US20200085902A1 (en) | Composition and method for treating itching, burning and discomfort of the skin | |
JP2015518886A (en) | Method for treating skin inflammatory disease | |
US8936814B2 (en) | Skin cream | |
US20230108251A1 (en) | Compositions and methods for the topical administration of spironolactone for the treatment of cutaneous signs of excess androgen and chronic stress response | |
CN113924084A (en) | pharmaceutical composition | |
WO2015040637A1 (en) | Improved coal tar formulation for treatment of dandruff and other scalp diseases and its method of preparation thereof | |
KR102751617B1 (en) | Composition for preventing, ameliorating or treating rosacea comprising isochlorogenic acid or salts thereof as an active ingredient | |
RU2426540C1 (en) | Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition | |
KR20090071529A (en) | Cosmetic composition having antibacterial and antifungal activity comprising vitamin K 1 or vitamin K 3 as an active ingredient | |
WO2022113072A1 (en) | Topical compositions comprising proton pump inhibitors (ppis) for the treatment of skin disorders | |
WO2021080527A1 (en) | Topical pharmaceutical compositions containing difluocortolone and isoconazole | |
EP1159956A2 (en) | Anhydrous topical skin preparations | |
KR20150128952A (en) | Topical compositions of flunisolide and methods of treatment | |
WO2016133471A1 (en) | A topical composition comprising mupirocin and dexpanthenol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |